Madison Square goes mad over Modi

September 29, 2014

New York, Sept 29: Prime Minister Narendra Modi on Sunday told a rapturous crowd of NRIs that Persons of Indian Origin (PIO) cardholders will get lifetime Indian visa and that American tourists will be given visa on arrival.

Madison ModiModi, who arrived at the packed Madison Square Garden to a rousing welcome, announced the merger of PIO and Overseas Citizens of India schemes to facilitate hassle-free travel to the Indian diaspora.

He announced that PIO cardholders staying in India on long-term basis will no longer have to report to the local police station.

At the unique event in the heart of Manhattan attended by some 20,000 cheering NRIs, Modi said that his big win in the Lok Sabha elections had come with a big responsibility for him which he would fulfil. Modi affirmed that India will move ahead at a rapid pace and lead the 21st century world.

Listing out India's advantages, the prime minister said that its three strengths were democracy, demographic dividend in which 65 per cent of its population was under 35 years, and the demand for India because it was a huge market. “My effort is to make development a mass movement. I am confident that we will succeed. This country is going to make rapid progress.

“There are many expectations from the new government. This government will be 100 per cent successful in fulfilling the aspirations of people,” he said amid loud cheers.

“My dream is to see every Indian family has a home by 2022,” he said.

Clearly with an eye on the younger generation, Modi said, “We will not do anything which will let you down.”

Attired in a saffron Nehru jacket and yellow kurta, the prime minister held the packed indoor stadium spellbound, asserting that “our attempt is to make development a people's movement.”

In his 75-minute-long speech in Hindi which he began with “Bharat Mata Ki Jai” while extending greetings for Navratri festival, Modi promised good governance, saying that after a gap of 30 years India has got a government at the Centre with a clear majority.

He also had a jibe at poll predictions in the run-up to the Lok Sabha elections. “No political pundit or opinion-maker could fathom such a verdict,” he said.

“Winning elections is not about any post or chair. It's a responsibility. Since taking over (as prime minister), I have not even taken a 15-minute vacation,” he said.

“You may not have voted in 2014 but I am sure that when the results were coming, you didn't sleep and you all celebrated,” he told the NRIs.

Promising a fast pace of development, Modi said, “There is no reason to be disappointed. India will progress very fast and the skills of our youth will take India ahead.”

Comments

Lilalilo
 - 
Monday, 5 Sep 2016

It is really a great piece of information.

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
February 21,2020

New Delhi, Feb 21: Global terror financing watchdog FATF on Friday decided continuation of Pakistan in the "Grey List" and warned the country that stern action will be taken if it fails to check flow of money to terror groups like the LeT and the JeM, sources said.

The decision has been taken at the Financial Action Task Force's plenary in Paris.

The FATF decided to continue Pakistani in the "Grey List". The FATF also warned Pakistan that if it doesn't complete a full action plan by June, it could lead to consequences on its businesses, a source said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 21,2020

Rome, Mar 21: Italy on Friday reported a record 627 new deaths from the novel coronavirus, taking its overall toll past 4,000 as the pandemic gathered pace despite government efforts to halt its spread.

The total number of deaths was 4,032, with the number of infections reaching 47,021.

Italy's previous one-day record death toll was 475 on Wednesday.

The nation of 60 million now accounts for 36.6 percent of the world's coronavirus deaths.

Italy has seen more than 1,500 deaths from COVID-19 in the past three days alone.

Its current daily death rate is higher than that officially reported by China at the peak of its outbreak around Wuhan's Hubei province.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.